TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development
TransCode Therapeutics Inc (NASDAQ: RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138.
TTX-MC138 is TransCode's lead therapeutic candidate for the treatment of metastatic solid tumors.